DARPA BAA-10-93 Formalized Predictive Viral Evolution Platform in 2010

The Defense Sciences Office structured PROPHECY to shift vaccine development from post-emergence observation to preemptive prediction of genotype-to-phenotype mappings, reassortment events, and mutation order. Contractors and laboratories were required to integrate high-throughput experimental validation with computational models capable of reproducing final viral population attributes. This architecture directly addressed the absence of reliable tools for anticipating evolutionary advantage in viral populations.

Primary records show the program explicitly targeted "the natural evolution of any virus," extending beyond influenza or coronaviruses to general platforms. Ralph Baric's laboratory received related funding streams years before the 2018 DEFUSE proposal, which replicated three spike-protein features later observed in SARS-CoV-2. The 2010 solicitation predates both events and establishes the technical requirements for predictive pipelines.

US biodefense incentives centered on reducing response latency for force protection and strategic surprise; the documented cost was expanded dual-use research infrastructure whose outputs could be repurposed. Competing state programs in China and Russia pursued parallel surveillance and synthetic biology capabilities under similar threat-framing rationales.

Next milestones include integration of PROPHECY-derived models into current DoD biosurveillance contracts and any declassification of validation datasets by 2027.